The FDA’s decision follows the results of a Phase 3 clinical trial concluding that patients who consumed the cannabis extract experienced greater mean pain reductions than did those who took opioids.
Region: Germany
“These findings expand the limited evidence on the use of cannabis-based medicines in elderly patients and complement previous clinical and observational studies on cannabinoids in pain medicine.”
Long-term cannabis treatment reduced patients’ TS symptoms without adversely impacting their cognitive performance or psychological well-being.
Compared to those receiving the placebo, patients receiving cannabis extracts demonstrated significant improvements in pain intensity, sleep quality, physical function, and overall quality of life.
Fifty-nine percent of respondents said they used cannabis “to suppress cravings for other [controlled] substances.”
Researchers “observed a substantial reduction in patient-reported pain intensity over time,” with pain scores falling most significantly in the cannabis-naïve subgroup.
The findings “support the potential of CBD to treat individuals with alcohol use disorder,” researchers concluded.
“Cannabis was rated as the most effective self-management strategy to reduce symptom intensity.”